Company intelligence / Profile preview

NeuTrace

Ownership: Private
Development stage: Commercial

Overview

NeuTrace developed a proprietary, device-neutral data integration platform ("EP Data Biome") designed to enable real-time artificial intelligence applications during cardiac electrophysiology procedures. The company's pipeline included several AI-enabled software products aimed at improving the accuracy, speed, safety, and outcomes of these procedures. No clinical trial results were reported prior to acquisition; products were in development.

Therapeutic areas: Cardiovascular
Modalities: DeviceAI-powered diagnostic software
Industry: Physiological Monitoring

Partnerships

nference

Beyond the preview

Go deeper on NeuTrace.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuTrace.

Explore the full profile